Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Early Stage Poor Prognosis CLL
NCT01127542Phase 2Terminated
- Sponsor
- The Christie
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by The Christie. Primary endpoint: Complete Remission with clearance of Minimal Residual Disease at 6 months. Started May 2010; status: terminated.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01127542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127542.